EntryPoint Capital LLC Boosts Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

EntryPoint Capital LLC grew its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 58.2% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 4,440 shares of the medical instruments supplier’s stock after buying an additional 1,633 shares during the quarter. EntryPoint Capital LLC’s holdings in LeMaitre Vascular were worth $409,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Smartleaf Asset Management LLC increased its position in shares of LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC increased its stake in shares of LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 117 shares during the last quarter. KBC Group NV raised its holdings in shares of LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 410 shares during the period. Empowered Funds LLC purchased a new position in LeMaitre Vascular in the fourth quarter valued at approximately $150,000. Finally, SG Americas Securities LLC bought a new position in LeMaitre Vascular during the fourth quarter valued at $158,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now owns 5,564 shares in the company, valued at $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.79% of the stock is currently owned by company insiders.

LeMaitre Vascular Price Performance

LMAT opened at $85.08 on Wednesday. The firm has a market capitalization of $1.92 billion, a P/E ratio of 46.49, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a one year low of $62.39 and a one year high of $109.58. The company has a fifty day moving average price of $93.94 and a 200-day moving average price of $94.48.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $55.81 million during the quarter, compared to analysts’ expectations of $55.99 million. On average, analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 27th. Investors of record on Thursday, March 13th will be given a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.94%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. The ex-dividend date is Thursday, March 13th. LeMaitre Vascular’s dividend payout ratio is 41.24%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on LMAT. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Oppenheimer downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price on the stock. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Finally, Lake Street Capital lifted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.25.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.